This miR also confers resistance to cisplatin treatment by downregulating TFAM [88] and, at the same time, promotes BC development and metastasis under hypoxic conditions by controlling the regulatory axis consisting of HIF-1, SNHG1, and TFAM [89]. This evidence concerns the gene TFAM and breast cancer.